Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
$154.02
+5.0%
$147.11
$57.99
$200.00
$5.88B-1.23199,643 shs214,303 shs
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
$40.50
$39.87
$12.74
$40.56
$6.27B1.112.15 million shsN/A
Harrow, Inc. stock logo
HROW
Harrow
$44.93
+5.1%
$37.39
$28.54
$54.85
$1.59B0.26781,620 shs946,436 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$99.93
+0.7%
$71.79
$23.30
$105.47
$6.18B2.112.05 million shs1.45 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
+5.04%-0.41%+7.44%-9.29%+157.82%
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
0.00%0.00%+2.22%+2.40%+182.53%
Harrow, Inc. stock logo
HROW
Harrow
+5.12%+9.19%+35.37%+26.81%+41.38%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+0.70%+1.60%+44.37%+99.38%+162.21%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
$154.02
+5.0%
$147.11
$57.99
$200.00
$5.88B-1.23199,643 shs214,303 shs
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
$40.50
$39.87
$12.74
$40.56
$6.27B1.112.15 million shsN/A
Harrow, Inc. stock logo
HROW
Harrow
$44.93
+5.1%
$37.39
$28.54
$54.85
$1.59B0.26781,620 shs946,436 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$99.93
+0.7%
$71.79
$23.30
$105.47
$6.18B2.112.05 million shs1.45 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
+5.04%-0.41%+7.44%-9.29%+157.82%
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
0.00%0.00%+2.22%+2.40%+182.53%
Harrow, Inc. stock logo
HROW
Harrow
+5.12%+9.19%+35.37%+26.81%+41.38%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+0.70%+1.60%+44.37%+99.38%+162.21%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
2.63
Moderate Buy$203.0031.80% Upside
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
2.21
Hold$41.332.06% Upside
Harrow, Inc. stock logo
HROW
Harrow
2.64
Moderate Buy$69.4354.53% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$84.30-15.64% Downside

Current Analyst Ratings Breakdown

Latest HROW, CNTA, TWST, and BLTE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/6/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
DowngradeOutperformIn-Line$102.00
6/29/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$60.00 ➝ $107.00
6/24/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Reiterated RatingSell (D-)
6/24/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetOverweight$65.00 ➝ $95.00
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$68.00 ➝ $89.00
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Initiated CoverageBuy$90.00
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Set Price Target$89.00
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$68.00 ➝ $89.00
6/15/2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
Reiterated RatingBuy$200.00
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Initiated CoverageBuy$90.00
6/11/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Initiated CoverageOverweight$85.00
(Data available from 7/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/AN/AN/AN/A$20.54 per shareN/A
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
N/AN/AN/AN/A$3.92 per shareN/A
Harrow, Inc. stock logo
HROW
Harrow
$272.30M6.15$0.91 per share49.45$1.41 per share31.87
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$376.57M16.52N/AN/A$7.84 per share12.75
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-$77.61M-$2.53N/A127.29N/AN/A-13.14%-12.88%8/10/2026 (Estimated)
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
-$197.53M-$1.79N/AN/AN/AN/A-60.37%-44.17%8/11/2026 (Estimated)
Harrow, Inc. stock logo
HROW
Harrow
-$5.14M-$0.41N/A20.80N/A-5.57%19.59%2.26%8/10/2026 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$77.67M-$1.33N/AN/AN/A-19.85%-26.73%-19.15%8/3/2026 (Estimated)

Latest HROW, CNTA, TWST, and BLTE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/3/2026Q3 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.50N/AN/AN/A$114.54 millionN/A
5/15/2026Q1 2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-$0.60-$0.34+$0.26-$0.68N/AN/A
5/11/2026Q1 2026
Harrow, Inc. stock logo
HROW
Harrow
-$0.43-$0.74-$0.31-$0.74$52.43 million$44.20 million
5/5/2026Q1 2026
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
-$0.38-$0.52-$0.14-$0.52N/AN/A
5/4/2026Q2 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.49-$0.71-$0.22-$0.71$107.64 million$110.72 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/AN/AN/AN/AN/A
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
N/AN/AN/AN/AN/A
Harrow, Inc. stock logo
HROW
Harrow
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/A
33.71
33.71
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
0.23
9.53
9.53
Harrow, Inc. stock logo
HROW
Harrow
10.30
2.48
2.30
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
2.70
2.42

Institutional Ownership

CompanyInstitutional Ownership
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
0.53%
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
82.01%
Harrow, Inc. stock logo
HROW
Harrow
72.76%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
13.29%
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
4.09%
Harrow, Inc. stock logo
HROW
Harrow
12.80%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.08%
CompanyEmployeesShares OutstandingFree FloatOptionable
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
1040.08 million34.76 millionNot Optionable
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
200154.73 million148.40 millionOptionable
Harrow, Inc. stock logo
HROW
Harrow
18037.28 million32.50 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99062.27 million60.35 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Belite Bio stock logo

Belite Bio NASDAQ:BLTE

$154.02 +7.39 (+5.04%)
Closing price 07/6/2026 04:00 PM Eastern
Extended Trading
$154.29 +0.27 (+0.18%)
As of 07/6/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Centessa Pharmaceuticals stock logo

Centessa Pharmaceuticals NASDAQ:CNTA

$40.50 0.00 (0.00%)
As of 06/25/2026

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Harrow stock logo

Harrow NASDAQ:HROW

$44.93 +2.19 (+5.12%)
Closing price 07/6/2026 04:00 PM Eastern
Extended Trading
$45.37 +0.44 (+0.99%)
As of 07/6/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$99.93 +0.69 (+0.70%)
Closing price 07/6/2026 04:00 PM Eastern
Extended Trading
$99.75 -0.18 (-0.18%)
As of 07/6/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.